Halozyme
HALO
552 hedge funds and large institutions have $6.05B invested in Halozyme in 2025 Q2 according to their latest regulatory filings, with 89 funds opening new positions, 180 increasing their positions, 217 reducing their positions, and 80 closing their positions.
24% more call options, than puts
Call options by funds: $26.3M | Put options by funds: $21.3M
11% more first-time investments, than exits
New positions opened: 89 | Existing positions closed: 80
0% more funds holding
Funds holding: 551 → 552 (+1)
3.77% less ownership
Funds ownership: 98.15% → 94.38% (-3.8%)
17% less repeat investments, than reductions
Existing positions increased: 180 | Existing positions reduced: 217
21% less capital inflows, than outflows
Capital inflows: $945M | Capital outflows: $1.2B
67% less funds holding in top 10
Funds holding in top 10: 9 → 3 (-6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$81.1M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$66.8M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$56.1M |
| 4 |
Jane Street
New York
|
+$52.7M |
| 5 |
Los Angeles Capital Management
Los Angeles,
California
|
+$50.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$221M |
| 2 |
JP Morgan Chase
New York
|
-$81.9M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
-$54M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
-$43.4M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$43.2M |
HALO Hedge Fund Activity: Q2 2025 in Review
552 of the 7,627 institutional investors tracked by Wall St. Rank reported a position in Halozyme (HALO) for Q2 2025, worth a combined $6.05B — down 22% from $7.74B a quarter earlier.
Buyers outnumbered sellers: 89 funds opened new HALO positions and 80 closed out — a net gain of 9 holders — while 180 added to existing stakes and 217 trimmed.
The largest buyer was Arrowstreet Capital, adding an estimated $81.1M. The largest seller was BlackRock, cutting an estimated $221M.
- 552 institutional investors held Halozyme (HALO) as of Q2 2025, up from 551 in Q1 2025.
- Funds reported $6.05B of Halozyme stock for Q2 2025, down 22% quarter-over-quarter.
- 89 funds opened new Halozyme positions in Q2 2025 and 80 closed out, a net change of +9 holders.
- The largest Halozyme buyer in Q2 2025 was Arrowstreet Capital, an estimated $81.1M added.
- The largest Halozyme seller in Q2 2025 was BlackRock, an estimated $221M sold.
Based on aggregated 13F filings for Q2 2025.